CRFA Awards 16 New Grants and Fellowships

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

ALEXANDRIA, Va--The Cancer Research Foundation of America (CRFA), a national, nonprofit organization dedicated to cancer prevention through scientific research and education, has awarded 16 new grants and fellowships totaling $528,605 for cancer prevention research. The money went to 14 institutions, most of it for 10 laboratory-based studies.

ALEXANDRIA, Va--The Cancer Research Foundation of America (CRFA), a national, nonprofit organization dedicated to cancer prevention through scientific research and education, has awarded 16 new grants and fellowships totaling $528,605 for cancer prevention research. The money went to 14 institutions, most of it for 10 laboratory-based studies.

The lone clinical trial funded--a randomized phase II chemoprevention study at the University of Colorado Health Sciences Center--will test selenium vs placebo in patients with localized prostate cancer. Drs. Karen Kelly and Nadine Mikhaeel-Kamel are the recipients.

Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Panelists smiling at camera on a blue background.
Panelists smiling at camera on a blue background.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Related Content